Ocugen shares surge 13.42% after-hours after positive Phase 2 OCU410 trial data for geographic atrophy.

Ocugen surged 13.42% in after-hours trading following the release of positive preliminary Phase 2 clinical trial data for its gene therapy OCU410 in treating geographic atrophy. The trial demonstrated a 46% reduction in lesion growth compared to untreated controls, with medium-dose patients showing a 54% reduction. These results, coupled with no serious adverse events reported, reinforced investor confidence in the therapy’s potential. While earlier news of a dilutive equity offering had pressured the stock, the strong clinical data appears to have overshadowed those concerns, driving the post-market rally. The positive outcome positions Ocugen for potential late-stage development and underscores its gene therapy platform’s viability, aligning with the stock’s upward momentum.